It is also noteworthy that no significant difference was observed in imaging features of the primary tumor between ROS1- and ALK-rearranged tumors, which may be attributed to the fact that these tumors have substantial similarities in both clinical attributes and response to crizotinib therapy. The gene discussed is ALK; the disease is neoplasm.